Introduction
Patients with epilepsy are more likely to have cognitive impairment than healthy individuals. The duration of epilepsy, underlying pathology, seizure frequency, and use of an antiepileptic drug (AED) influence the cognitive function of patients with epilepsy. AED-induced cognitive impairment appears to be less common in patients taking newer AEDs than in those taking older AEDs. 1, 2 Lamotrigine (LTG) is an AED that appears to be associated with fewer cognitive and behavioral changes than are many other AEDs. 3, 4 Existing data suggest that the cognitive deficits commonly associated with AED therapy are rarely observed in patients receiving LTG monotherapy. 5, 6 When LTG is used as an add-on therapy, existing cognitive problems are not exacerbated, and, in some cases, become less severe. [5] [6] [7] A randomized, monotherapy clinical trial of newly diagnosed epilepsy patients is the best method to assess the cognitive impact of AEDs. Such a study is not confounded by the effect of concurrent or previous AED use, and allows accurate collection of baseline data, which are required to determine whether a drug affects cognitive processing. 8 A large number of cognitive studies have investigated
Purpose: In this prospective study, we compared the long-term cognitive and behavioral effects of lamotrigine (LTG) and carbamazepine (CBZ) in patients with newly diagnosed or untreated partial epilepsy.
Methods: This was a multicenter, open-label, randomized study that compared monotherapy with LTG and CBZ in newly diagnosed or untreated patients with partial epilepsy. We employed an 8-week titration period and a 40-week maintenance period. Neuropsychological tests, Symptom Check List-90, and QOLIE-31 were assessed at baseline, 16 weeks, and 48 weeks after drug treatment. A group-by-time interaction was the primary outcome measure and was analyzed by use of the linear mixed model. Results: A total of 110 patients were eligible and 73 completed the 48-week study (LTG, n = 39; CBZ, n = 34). Among the cognitive tests, significant group-by-time interaction was identified only in phonemic fluency of Controlled Oral Word Association Task (p = 0.0032) and Stroop Color-Word Interference (p = 0.0283), with a significant better performance for LTG group. All other neuropsychological tests included did not show significant group-by-time interactions. Among the subscales of Symptom Check List-90, significant group-by-time interactions were identified in Obsessive-Compulsive (p = 0.0005), Paranoid Ideation (p = 0.0454), Global Severity Index (p = 0.0194), and Positive Symptom Total (p = 0.0197), with a significant improvement for CBZ group. QOLIE-31 did not show significant groupby-time interactions. Conclusion: Our data suggest that epilepsy patients on LTG have better performance on phonemic fluency and the task of Stroop Color-Word Interference than do patients on CBZ, whereas patients on CBZ had more favorable behavioral effects on two subscales and two global scores of Symptom Check List-90 than did patients on LTG. ß 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
LTG, but few randomized long-term trials have compared LTG and carbamazepine (CBZ) monotherapy in patients with newly diagnosed epilepsy. Brodie et al. 9 investigated the long-term effects of LTG and CBZ on the cognitive function of patients with newly diagnosed epilepsy, and concluded that LTG may have a more favorable effect on cognitive function. However, the cited study was not published in full, and only the abstract is available. The current randomized prospective investigation was designed to compare the long-term cognitive and behavioral effects of LTG and CBZ in adult patients with newly diagnosed or untreated partial epilepsy. CBZ was chosen as the active comparator because this is often the treatment-of-choice for monotherapy of patients with partial epilepsy. With the exception of slowing the speed of information processing, CBZ does not significantly impair cognitive function during long-term treatment of epilepsy. 
Study design
In this study, we analyzed the cognitive data of newly diagnosed or untreated patients with partial epilepsy by use of a multicenter, open-label, randomized, parallel-group comparison of LTG and CBZ, given as monotherapy. This study consisted of an 8-week titration period and a 40-week maintenance period. Cognitive data from patients who completed the entire 48 weeks of the trial were evaluated.
Patients
Patients, aged 16-60 years, with newly diagnosed partial epilepsy were eligible for inclusion. We also included patients with partial epilepsy who were recently untreated for at least one year. All enrolled patients had at least one partial seizure, with or without secondary generalization, in the 12 months before commencement of the study. We excluded patients who used any AED treatment within the past one year (except as an emergency treatment for 2 weeks); those with full-scale intelligence quotient (FSIQ) less than 70; and those with idiopathic generalized epilepsy, an active CNS infection, any progressive CNS disease, or any medical or neurological disorder that required frequent changes in medication or dosage. The study was approved by local ethics committees and was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Each participant gave written informed consent.
Dosing
Patients were randomized to monotherapy with LTG or CBZ in a 1:1 ratio, in blocks of four. During the 8-week titration period, patients received LTG as follows: 25 mg/day for weeks 1-2, 50 mg/ day for weeks 3-4, 100 mg/day for weeks 5-6, and 200 mg/day for weeks 7-8. During the maintenance period, the LTG dose was increased to a maximum of 500 mg/day if the patient continued to experience seizures. Patients receiving CBZ were dosed as follows: 100 mg/day for weeks 1-2, 200 mg/day for weeks 3-4, 400 mg/day for weeks 5-6, and 600 mg/day for weeks 7-8. During the maintenance period, the CBZ dose was increased to a maximum of 1200 mg/day if the patient continued to experience seizures. Controlled-release preparations of CBZ were used. Exit criteria based on insufficient efficacy were: (i) occurrence of a seizure during the maintenance period despite administration of the drug at the maximum allowed dose or the maximum tolerated dose and (ii) a maximum tolerated dose less than 100 mg/day of LTG or 400 mg/day of CBZ. Both drugs were administered as two divided doses per day. The doses of drugs were determined by seizure recurrence and drug tolerance.
Neuropsychological tests
Cognitive function was evaluated at baseline, at week 16, and at week 48 using a range of neuropsychological tests that measure general intellectual ability, learning and memory, attention, and executive function. General intellectual ability was assessed employing the short form of the Korean Wechsler Adult Intelligence ScaleRevised using four subtests of the scale: Vocabulary, Arithmetic, Picture Completion, and Block Design. 12 Verbal learning and memory
were assessed with the Korean California Verbal Learning Test
13
: List A acquisition, immediate and delayed free recall, recognition hits, and discriminability. Visuospatial constructional ability and visuospatial memory were assessed with the Rey Complex Figure in which participants had to say as many words as possible from a category in 60 s. The semantic categories were words related to animals and supermarkets, and the phonemic categories were words that began with the Korean letters q (g or k), * (o), and f (s). Subjective psychological symptoms and health-related qualityof-life were assessed with the Symptom Check List-90 16 (SCL-90) and the QOLIE-31. 17 The SCL-90 is a 90-item multidimensional questionnaire designed to screen for a broad range of psychological problems. The subscales included are nine primary symptom dimensions: Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Depression, Anxiety, Anger-Hostility, Phobic Anxiety, Paranoid Ideation, and Psychoticism. Three ''global'' scores are also obtained: the Global Severity Index, The Positive Symptom Distress Index, and the Positive Symptom Total. The subscales of QOLIE-31 include evaluation of seizure worry, overall quality-oflife, emotional well-being, energy/fatigue, cognitive functioning, medication effects, and social functioning.
Statistical analyses
All patients who were given neuropsychological tests at baseline and at 16-and 48-week follow-ups were included in this analysis. The primary outcome measure was a group-by-time interaction, which was analyzed using a linear mixed model. Analyses of group effects and time effects were performed only when there was a significant group-by-time interaction. The model included treatment group, time, and group-time effects as fixed, and hospital effects as random. A covariance pattern was constructed for repeated observations by the same patients. Stroop Color-Word Interference was analyzed after log-transformation, because it has a right-skewed distribution. The model included adjusted variables as fixed effects. The adjusted variables were age, gender, years of education, FSIQ, and presence of seizure recurrence during the maintenance period. Significance level was set at p 0.05. Data were analyzed using SAS version 9.1 (SAS Institute, Cary, NC).
Results

Demographics and clinical data
We enrolled 116 patients, with 57 randomized to receive LTG and 53 to receive CBZ (Fig. 1) . Six patients dropped out before randomization because of withdrawal of consent (4 patients) and low FSIQ scores (2 patients). Seventy-three patients successfully continued treatment until the week-48 follow-up (LTG, n = 39, 68.4%; CBZ, n = 34, 64.2%). In the LTG group, the reasons for discontinuation were withdrawal of consent (n = 7), adverse events (n = 4), lack of efficacy (n = 4), loss to follow-up (n = 2), and protocol violation (FSIQ less than 70) (n = 1). All adverse events were developing skin rashes. In the CBZ group, the reasons for discontinuation were loss to follow-up (n = 7), adverse events (n = 7), lack of efficacy (n = 2), withdrawal of consent (n = 2), protocol violation (more than 2 weeks of emergency treatment) (n = 1). Among adverse events in CBZ group, skin rashes were in 5 patients, car accident (not directly related to CBZ) was in one patient, and mitral stenosis (not directly related to CBZ) was in one patient. Patients who completed the study were well matched with respect to demographic and clinical characteristics ( Table 1) . The percentage of patients with no seizures was not significantly different between the groups during the maintenance period (71.8% LTG, 64.7% CBZ; p > 0.05). At the 16-week and 48-week follow-ups, the average daily dose of medication was 217 mg (SD = 45 mg) and 236 mg (SD = 81 mg) in the LTG group, and 605 mg (SD = 104 mg) and 647 mg (SD = 164 mg) in the CBZ group.
Cognitive data
Significant group-by-time interaction was identified only in the phonemic fluency of COWAT (p = 0.0032) and Stroop ColorWord Interference (p = 0.0283), with the LTG group performing significantly better ( Table 2 ). The CBZ and LTG groups did not differ significantly at baseline. However, the LTG group was significantly better than the CBZ group in phonemic fluency at both 16 (p = 0.0062) and 48 (p = 0.0032) weeks and in Stroop Color-Word Interference (p = 0.0229) at 48 weeks (Table 2) . Time effects were significant only in the LTG, not in the CBZ, group. In the LTG group, phonemic fluency was significantly better, relative to baseline, at 16 (p = 0.0003) and 48 (p < 0.0001) weeks, and Stroop Color-Word Interference was significantly better at 48-weeks (p = 0.0002). All other cognitive tests, including those of language and memory, did not show significant group-by-time interactions (Tables e-1 [ 
Psychological and quality-of-life data
Significant group-by-time interactions were identified in Obsessive-Compulsive (p = 0.0005), Paranoid Ideation (p = 0.0454), Global Severity Index (p = 0.0194), and Positive Symptom Total (p = 0.0197) scores of the SCL-90 (Table 3) , with significant improvements in the CBZ group. Obsessive-Compulsive subscale did not differ between the CBZ and LTG groups at baseline, but was significantly better in the CBZ than in the LTG group at 48 weeks (p = 0.0427). In addition, the Obsessive-Compulsive subscale was significantly improved at 48-weeks, compared with baseline, in the CBZ (p = 0.0012), but not in the LTG, group. Paranoid Ideation, Global Severity Index, and Positive Symptom Total showed significant time effects but not group effects. All were significantly improved, relative to baseline, at 48-weeks (p < 0.05) in the CBZ group but not in the LTG group. In contrast, the LTG group showed a significant improvement, relative to baseline, on Positive Symptom Total at 16 (p = 0.0129) but not at 48 weeks. The other dimensions of the SCL-90 (Table e-3) and the total and subscale scores of the QOLIE-31 (Table e-4) did not show any significant group-by-time interactions.
Discussion
We compared the cognitive and behavioral long-term effects of LTG and controlled-release CBZ in adult patients with newly diagnosed or untreated partial epilepsy. LTG-treated patients performed better than CBZ-treated patients on phonemic verbal fluency of COWAT and selective attention measured by Stroop Color-Word Interference, but the two groups did not differ in language, memory function, and other executive functions. In contrast, the CBZ group showed more positive behavioral effects than did the LTG group.
LTG has not been associated with impaired cognitive functioning, and use of LTG may lead to improvements in cognition and associated measures of health-related quality of life. [4] [5] [6] However, few randomized monotherapy studies have assessed the long-term cognitive impact of LTG, especially in patients with newly diagnosed epilepsy. The short-term cognitive effects of LTG have been evaluated in healthy volunteers, 5, 18 as add-on therapy, 6,7 and in comparison with active comparators other than CBZ. 5, 6 Long term treatment with LTG may result in types of cognitive impairments that cannot be observed during short-term treatment. 4 Except for an abstract, 9 this is the first study to compare the long-term effects of LTG and CBZ on the cognitive function of patients newly diagnosed with epilepsy. That study 9 Interference were better in LTG-treated than in CBZ-treated patients. Our findings, along with those reported previously, 9 suggest that LTG may have a favorable long-term effect on cognitive function when compared with CBZ. Short-term volunteer studies using a double-blind, randomized crossover design with two 10-or 12-week treatment periods were performed to evaluate the relative cognitive and behavioral effects of LTG compared with CBZ 18 or topiramate, 5 respectively. In both studies, the LTG group showed significantly better performance on a wide variety of objective and subjective neuropsychological measures when compared with CBZ and topiramate, respectively. A double-blind, randomized, prospective comparison of the cognitive effects of LTG and topiramate, which was used as adjunctive therapy in adults with epilepsy, with an 8-week titration period followed by an 8-week maintenance period, showed that LTG resulted in better performance than topiramate on the COWAT, Stroop Color-Word Interference, and Symbol-Digit Modalities tests. 6 Although our study did not include a no-drug group, the significant difference between the LTG and CBZ groups was likely caused by decreased performance on the phonemic verbal fluency and Stroop Color-Word Interference tasks in the CBZ group, which manifested as negation of the practice effect. The practice effect is one of the most significant confounding influences encountered in studies that employ follow-up testing performance. Practice effects can occur even after a time interval of nearly 1 year. 19 Previous shortterm studies on healthy volunteers also indicated adverse cognitive effects of CBZ compared with LTG or gabapentin. 18, 20 Our CBZ group showed more positive behavioral effects than did the LTG group. Among the subscales and global indexes of SCL-90, Obsessive-Compulsive, Paranoid Ideation, Global Severity Index, and Positive Symptom Total found that only CBZ patients showed significant improvements at 48 weeks. In contrast, the LTG group showed significant improvements on the Positive Symptom Total only at 16 weeks, but not at 48 weeks, compared with baseline. CBZ was initially developed to treat individuals with epilepsy but was subsequently found to have diverse psychotropic effects, most notably in mood-stabilization. [21] [22] [23] In addition, CBZ has been reported to effectively reduce Obsessive-Compulsive symptoms in patients with epilepsy 24, 25 and may have antidepressant effects. 26, 27 Thus, CBZ appears to elicit diverse neurochemical effects, but which of these effects is most closely related to its antidepressant effects, compared with its antimanic and anticonvulsant effects, remains to be determined. 28 Previous studies of LTG in patients with epilepsy showed an apparently independent improvement in depression apart from reductions in seizure frequency. [29] [30] [31] [32] Most of the cited studies assessed only short-term drug effects (less than 7 months). In this study, the LTG group also showed significant improvements on the Positive Symptom Total of SCL-90. But these favorable behavioral effects were observed only at 16 weeks, but not at 48 weeks, when compared with baseline. We need further long-term studies to clarify the long-term effects of LTG on mood in patients with epilepsy. LTG has been also shown to be effective for treatment of bipolar disorder based on long-term trials. 33, 34 However, this study did not demonstrate long-term effects of LTG on mood and behavior. The reason for this discrepancy was unclear. A nonrandomized study in 35 adults with partial epilepsy found no appreciable effects on mood changes, when measured with various established depression and anxiety scales, with LTG of mean 150 mg/day for approximately 3.5 months. 35 This may have been a result of the low LTG dosages used in these patients. In our study, LTG dosages were not low. The mean dosage of the study was 236 mg/day at week-48. An 18-month trial of LTG maintenance treatment in recently depressed patients with bipolar I disorder showed that LTG 200 mg/day group had significant efficacy including time to intervention for a mood episode and one-year intervention-free rate for depression. 34 Another possible explanation is that LTG could have different effects on mood in different disease entities. Several previous studies using validated scales showed that LTG treatment was associated with improved quality-of-life. 4, 5, 18, 36 However, very few randomized controlled studies have examined the long-term effects of AEDs on quality-of-life. Marson et al. 37 reported 2-year follow-up results on quality-of-life in adult patients taking CBZ or other new AEDs as part of a large, unblinded, randomized controlled trial. The cited authors found no significant differences in quality-of-life among those taking different drugs. Their results were consistent with those in this study. Another study involved a double-blind comparison of LTG and CBZ in patients with newly diagnosed epilepsy, in which 260 patients were randomized to 48 weeks of LTG or CBZ. 38 Quality-of-life was measured using the modified SEALS Inventory. When changes in quality-of-life were evaluated within groups for patients who completed this 48-week study, the SEALS scores in the LTG group improved significantly from baseline on all subscales after 48 weeks, but CBZ patients experienced no significant change in subsequent SEALS assessments. These findings are somewhat inconsistent with our results. We found no significant differences in quality-of-life among those taking CBZ or LTG.
The results of this study must be interpreted with some caution. First, the sensitivity of detecting putative changes after AED treatment may differ by type of cognitive tests. 39 Therefore, the lack of differential effects could be caused by non-sensitive cognitive tasks. In contrast, mood and subjective symptoms may be more sensitive than objective cognitive tests to the effects of AED. Second, the effects on the 34% of randomized subjects who did not complete the study were not considered. Some of these non-completers could dropped out, withdraw their consent, or be lost follow-up due to cognitive or mood adverse events. Third, our data were pooled from multiple hospitals to increase the number of patients. We believe, however, that confounding factors were minimized because neuropsychologists from each hospital met three times before the start of the study to minimize methodological differences and inter-hospital effects. Fourth, this was a randomized but unblinded study.
